Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04895735 · ClinicalTrials.gov registry record · Phase 2

MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer

A Phase 2 study of Adenoid Cystic Carcinoma and Recurrent Salivary Gland Carcinoma, sponsored by Mayo Clinic.

Active
Registry status
Phase 2
Development phase
45
Enrollment target
2
Study locations

NCT04895735 is a Phase 2 study of Adenoid Cystic Carcinoma and Recurrent Salivary Gland Carcinoma that is active but no longer recruiting, run by Mayo Clinic. The registered enrollment target is 45 participants, below the 125-participant average among 16 other Adenoid Cystic Carcinoma trials with a reported enrollment target (64% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04895735, a Phase 2 study of Adenoid Cystic Carcinoma and Recurrent Salivary Gland Carcinoma, is active but no longer recruiting, sponsored by Mayo Clinic.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
45 participants
Enrollment target
2
Study locations

Study Summary

This phase II trial studies the effect of pemetrexed and pembrolizumab in treating patients with salivary gland cancer that has come back (recurrent) and/or has spread to other places in the body (metastatic). Chemotherapy drugs, such as pemetrexed, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The purpose of this study is to evaluate whether pembrolizumab, an immunotherapy drug, in combination with the chemotherapy drug, pemetrexed, has an effect on advanced salivary gland cancer.

Conditions Studied

Adenoid Cystic Carcinoma Recurrent Salivary Gland Carcinoma Metastatic Salivary Gland Carcinoma Stage IV Major Salivary Gland Cancer AJCC v8

Interventions

  • BIOLOGICAL Pembrolizumab
  • PROCEDURE Biospecimen Collection
  • PROCEDURE Computed Tomography
  • PROCEDURE Positron Emission Tomography
  • DRUG Pemetrexed Disodium

Study Locations (2)

Arizona

  • Mayo Clinic in Arizona - Scottsdale

Minnesota

  • Mayo Clinic in Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 2021-07-23
Est. Completion 2028-02-28
Phase Phase 2

Sponsor

Mayo Clinic

2,844 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04895735

The ClinicalTrials.gov registry entry for NCT04895735 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 125-participant average among 16 other Adenoid Cystic Carcinoma trials with a reported enrollment target (64% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Adenoid Cystic Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.

NCT04895735 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Arizona, Minnesota.

Frequently Asked Questions

What is clinical trial NCT04895735 about?

NCT04895735 is a clinical study titled "MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer". This phase II trial studies the effect of pemetrexed and pembrolizumab in treating patients with salivary gland cancer that has come back (recurrent) and/or has spread to other places in the body (metastatic). Chemotherapy drugs, such as pemetrexed, work in different ways to stop the growth of tumor...

What is the current status of trial NCT04895735?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2021-07-23. Estimated completion is 2028-02-28.

What conditions does trial NCT04895735 study?

This clinical trial studies the following conditions: Adenoid Cystic Carcinoma, Recurrent Salivary Gland Carcinoma, Metastatic Salivary Gland Carcinoma, Stage IV Major Salivary Gland Cancer AJCC v8.

What interventions are being tested in trial NCT04895735?

The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Positron Emission Tomography (PROCEDURE), Pemetrexed Disodium (DRUG).

Who is sponsoring clinical trial NCT04895735?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04895735 being conducted?

This trial has 2 study locations across Arizona, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Adenoid Cystic Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Adenoid Cystic Carcinoma

All registered trials for this condition

Recurrent Salivary Gland Carcinoma

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.